TNFRSF18 and B-cell chronic lymphocytic leukemia: In addition to the possible impact on survival, several clinical trials investigate GITR as therapeutic target using an anti-GITR antibody (NCT01239134, NCT02598960), which, based on our data, might be a promising approach for GITR+ CLL as well.